Valuation: Sionna Therapeutics, Inc.

Market Cap 2.23B 1.95B 1.8B 1.66B 3.13B 215B 3.19B 21.5B 8.46B 105B 8.38B 8.19B 362B P/E 2026 *
-19.7x
P/E 2027 * -18.6x
Enterprise Value 1.95B 1.7B 1.57B 1.45B 2.73B 188B 2.79B 18.77B 7.38B 91.85B 7.31B 7.15B 316B EV / Sales 2026 *
-
EV / Sales 2027 * 655x
Free-Float
93.15%
Yield 2026 *
-
Yield 2027 * -
1 day+9.10%
1 week+9.10%
Current month+12.32%
1 month+34.52%
3 months+13.48%
6 months+26.34%
Current year+20.10%
1 week 41.68
Extreme 41.685
51
1 month 37.28
Extreme 37.28
51
Current year 32.26
Extreme 32.26
51
1 year 16.38
Extreme 16.38
51
3 years 7.26
Extreme 7.255
51
5 years 7.26
Extreme 7.255
51
10 years 7.26
Extreme 7.255
51
Manager TitleAgeSince
Corporate Officer/Principal - 2019-07-31
Corporate Officer/Principal - 2019-07-31
Chief Executive Officer 55 2021-04-30
Director TitleAgeSince
Director/Board Member 51 2019-11-30
Director/Board Member 44 2019-11-30
Director/Board Member 52 2020-05-31
Date Insider Type Main position Quantity % Market Cap.
7/7/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
7/7/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
7/6/26 Fiscal year

General Counsel

30,750 0.0681%
Change 5-day change 1-year change 3-year change Capi.($)
+9.10%+9.10%+169.56% - 2.23B
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +1.08%+0.94%+217.14%+179.48% 20.84B
Weighted average by Cap. +0.33%+0.45%+171.41%+187.42%

Financials

2026 *2027 *
Net sales - 3M 2.62M 2.42M 2.23M 4.2M 289M 4.3M 28.92M 11.37M 141M 11.27M 11.02M 487M
Net income -119M -104M -96.11M -88.59M -167M -11.48B -171M -1.15B -452M -5.62B -448M -438M -19.35B -138M -120M -111M -102M -193M -13.27B -197M -1.33B -522M -6.5B -517M -506M -22.37B
Net Debt -283M -248M -228M -211M -397M -27.29B -406M -2.73B -1.07B -13.36B -1.06B -1.04B -46B -266M -233M -215M -198M -373M -25.64B -381M -2.57B -1.01B -12.56B -1B -978M -43.23B
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
26-07-17 US$49.41 +9.10% 1,139,315
26-07-16 US$45.29 +2.05% 1,096,320
26-07-15 US$44.38 +4.20% 522,135
26-07-14 US$42.59 -3.09% 275,951
26-07-13 US$43.95 -2.96% 415,293
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
49.41USD
Average target price
51.60USD
Spread / Average Target
+4.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SION Stock